Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

Trial Profile

Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs Gemcitabine (Primary) ; Vismodegib (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Planned end date changed from 1 Jun 2016 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Planned End Date changed from 1 Jul 2011 to 1 Jun 2016 as reported by ClinicalTrials.gov. (NCT01195415 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top